532523:BOM
Biocon Ltd
₹351.50
arrow_upward
+0.07%(+0.25) 1D
10월 15일, 오후 3시 50분 26초 GMT+5:30 · INR
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto532523의 주요 통계 생성 중...
시가
₹354.05
고가
₹356.05
저가
₹350.25
시가총액
4211.85억
평균 거래량
69.84만
거래량
7.60만
배당금
0.14%
분기 배당금
₹0.12
배당락일
2026. 7. 3.
주가수익률
104.06
52주 최고가
₹447.00
52주 최저가
₹337.95
EPS
₹3.38
유통 주식수
6.00억
직원 수
2만
시가
₹354.05
고가
₹356.05
저가
₹350.25
시가총액
4211.85억
평균 거래량
69.84만
거래량
7.60만
배당금
0.14%
분기 배당금
₹0.12
배당락일
2026. 7. 3.
주가수익률
104.06
52주 최고가
₹447.00
52주 최저가
₹337.95
EPS
₹3.38
유통 주식수
6.00억
직원 수
2만
뉴스 기사
웹 소스 및 뉴스 파트너 제공
Dalal Street Investment Journal
·
1일 전
Biocon settles Genentech disputes, secures 2027 EU and 2028 US launch window for Pebrilzo
프로필
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Biocon Ltd에 관한 정보